• Atom Bioscience & Pharmaceutical

  Participated · Series D · Oct 2023

  Atom Bioscience's lead product, ABP-671, is an orally administered URAT1 inhibitor in clinical development for chronic gout; it has demonstrated strong Phase 2 efficacy across doses from 1–12 mg once daily. At 6–8 mg doses 100% of subjects achieved sUA <6 mg/dL, and at 12 mg 100% achieved sUA <4 mg/dL; efficacy was maintained up to 24 hours with once-daily dosing and no significant adverse effects versus placebo. ABP-671 was generally well tolerated with mostly grade 1 adverse events and a human mass-balance study showed the drug is largely excreted unchanged without metabolites similar to benzbromarone. The company plans global pivotal clinical trials for ABP-671 and intends to investigate use in refractory gout. A second small molecule, ABP-745, has shown efficacy in animal anti-inflammation models; Atom submitted a Pre-IND to the U.S. FDA in August and expects to file INDs in the U.S. and China in November. Financially, Atom completed a D-round of approximately $83 million and has now raised nearly $165 million to date to advance its pipeline. Atom Bioscience is a clinical-stage biotech developing best-in-class small-molecule therapeutics for inflammatory and metabolic diseases. Its lead candidate, ABP-671, is a URAT1 inhibitor being developed to treat hyperuricemia and chronic gout and is moving into a global Phase III trial. In a Phase IIa exploratory analysis, a low daily dose of ABP-671 enabled about 95% of patients to achieve serum uric acid (sUA) below 6 mg/dL, with many reaching 4–5 mg/dL; the drug has shown an attractive safety profile and activity at low doses. The company also has ABP-6016, a small molecule for NASH that has shown notable potency and an excellent safety profile in preclinical/early testing. Atom plans to use the Series C proceeds to support the ABP-671 Phase III and continued preclinical and clinical development of its pipeline. Financially, the company closed a $45 million Series C and has raised $87 million in total since its 2012 founding. Founded in March 2012 as a Sino‑US joint‑venture, Jiangsu Xinyuansu centers on discovery and development of innovative medicines. Its lead program is ABP‑601, a 1.1 class anti‑gout candidate now preparing and filing an IND in the United States. Preclinical data reportedly show ABP‑601 promotes uric acid excretion far superior to marketed drugs in animals while lacking liver, kidney, gastrointestinal, and cardiovascular toxicities, and demonstrating strong developability. The company’s gout platform includes both uric‑acid‑excretion and uric‑acid‑production‑inhibition approaches. Other pipeline programs target breast cancer and NASH, with some candidates approaching preclinical or clinical research. Recently completed financing will support global clinical advancement of ABP‑601 and continued development of other pipeline assets.

No current team members are available.